Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Cyproheptadine HCl ( also known as Periactin; Eiproheptadine; Periactinol; Dronactin; Peritol), is a hydrochloride salt form of cyproheptadine that is used as an antimuscarinic and histamine receptor antagonist (antihistamine) to treat pituitary-dependent Cushing's syndrome, anorexia, pruritic dermatoses, and postgastrectomy dumping syndrome.
Targets |
5-HT2 Receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C21H22CLN
|
|
---|---|---|
Molecular Weight |
323.86
|
|
Exact Mass |
323.14
|
|
CAS # |
969-33-5
|
|
Related CAS # |
Cyproheptadine hydrochloride sesquihydrate; 41354-29-4; Cyproheptadine; 129-03-3
|
|
Appearance |
White to off-white solid powder
|
|
SMILES |
CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl
|
|
InChi Key |
ZPMVNZLARAEGHB-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H21N.ClH/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;/h2-11H,12-15H2,1H3;1H
|
|
Chemical Name |
1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0878 mL | 15.4388 mL | 30.8775 mL | |
5 mM | 0.6176 mL | 3.0878 mL | 6.1755 mL | |
10 mM | 0.3088 mL | 1.5439 mL | 3.0878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02418949 | Active Recruiting |
Drug: Placebo for Cyproheptadine Drug: Cyproheptadine |
Stroke Hemiparesis Muscle Spasticity |
Shirley Ryan AbilityLab | November 2015 | Not Applicable |
NCT06175273 | Not yet recruiting | Drug: Cyproheptadine Drug: Dronabinol Other: Standard of Care |
Pediatric Cancer Muscle Loss Malnutrition, Child |
Corey Hawes | January 2024 | Phase 2 Phase 3 |
NCT05469165 | Recruiting | Drug: Cyproheptadine 4 Mg Oral Tablet Other: Placebo |
Ischemic Mitral Regurgitation | Laval University | June 20, 2023 | Phase 2 |
NCT06147622 | Not yet recruiting | Drug: Prazosin + cyproheptadine Drug: KT110 |
Alcohol Use Disorder | Kinnov Therapeutics | February 2024 | Phase 1 |
NCT00066248 | Completed | Drug: cyproheptadine hydrochloride Drug: megestrol acetate |
Brain Tumor Cachexia Leukemia Lymphoma |
University of South Florida | June 2003 | Phase 2 |
Combination of Cyproheptadine and pizotifen inhibits serotonin-enhanced ADP-induced human platelet aggregation in vitro. PLoS One . 2014 Jan 23;9(1):e87026. td> |
Cyproheptadine and pizotifen inhibit serotonin-enhanced ADP-induced mouse platelet aggregation in vitro. PLoS One . 2014 Jan 23;9(1):e87026. td> |
Cyproheptadine, and pizotifen inhibit intracellular calcium elevation and Src activation in human platelets in vitro. PLoS One . 2014 Jan 23;9(1):e87026. td> |